Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: thrombin inhibiting aptamers - ARCA biopharm/Archemix

Drug Profile

Research programme: thrombin inhibiting aptamers - ARCA biopharm/Archemix

Alternative Names: ARC-2172

Latest Information Update: 04 Oct 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer ARCA biopharma Inc
  • Class Nucleotide aptamers
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 04 Oct 2012 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
  • 01 Feb 2008 A lead compound from this programme has entered clinical trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top